跳至主要内容
临床试验/NCT00228605
NCT00228605已完成3 期

An Open-Label 12 Month Study to Evaluate the Safety, Tolerability and Efficacy of OraVescent Fentanyl Citrate for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Noncancer Pain

Cephalon72 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2005年3月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
500
试验地点
72
主要终点
Safety and tolerability when used over a 12-month period for the management of breakthrough pain in opioid tolerant patients

研究概览

简要总结

The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Chronic pain diagnosis
  • Opioid tolerant
  • Has on average 1-4 breakthrough pain episodes per day

排除标准

  • Drug abuse history
  • Cardiopulmonary disease
  • Monoamine oxidase inhibitors (MAOIs)
  • Expected to have surgery to relieve the pain

结局指标

主要结局

Safety and tolerability when used over a 12-month period for the management of breakthrough pain in opioid tolerant patients

次要结局

  • Assess the patients' quality of life through questionnaires
  • Assess the patients' overall medication preferences
  • Assess the patients' overall medication performance

研究者

发起方
Cephalon
申办方类型
Industry

研究点 (72)

Loading locations...

相似试验